Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55α holoenzymes during mitotic exit.
Kerstin SchottNina V FuchsRita DeruaBijan MahboubiEsther SchnellbächerJanna SeifriedChristiane TonderaHeike SchmitzCaitlin ShepardAlberto Brandariz-NuñezFelipe Diaz-GrifferoAndreas ReuterBaek KimVeerle JanssensRenate KönigPublished in: Nature communications (2018)
SAMHD1 is a critical restriction factor for HIV-1 in non-cycling cells and its antiviral activity is regulated by T592 phosphorylation. Here, we show that SAMHD1 dephosphorylation at T592 is controlled during the cell cycle, occurring during M/G1 transition in proliferating cells. Using several complementary proteomics and biochemical approaches, we identify the phosphatase PP2A-B55α responsible for rendering SAMHD1 antivirally active. SAMHD1 is specifically targeted by PP2A-B55α holoenzymes during mitotic exit, in line with observations that PP2A-B55α is a key mitotic exit phosphatase in mammalian cells. Strikingly, as HeLa or activated primary CD4+ T cells enter the G1 phase, pronounced reduction of RT products is observed upon HIV-1 infection dependent on the presence of dephosphorylated SAMHD1. Moreover, PP2A controls SAMHD1 pT592 level in non-cycling monocyte-derived macrophages (MDMs). Thus, the PP2A-B55α holoenzyme is a key regulator to switch on the antiviral activity of SAMHD1.
Keyphrases
- cell cycle
- antiretroviral therapy
- induced apoptosis
- cell cycle arrest
- cell proliferation
- human immunodeficiency virus
- hiv infected
- hiv positive
- hepatitis c virus
- hiv testing
- high intensity
- endothelial cells
- mass spectrometry
- protein kinase
- endoplasmic reticulum stress
- cell death
- men who have sex with men
- signaling pathway
- cancer therapy
- south africa